# Safety and Efficacy of Once-daily Oral Administrations of TZP-102 for Gastroparesis in Patients With Diabetes Mellitus

> **NCT00889486** · PHASE2 · COMPLETED · sponsor: **Tranzyme, Inc.** · enrollment: 92 (actual)

## Conditions studied

- Gastroparesis
- Diabetes Mellitus

## Interventions

- **DRUG:** TZP-102
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00889486
- **Lead sponsor:** Tranzyme, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2012-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00889486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00889486, "Safety and Efficacy of Once-daily Oral Administrations of TZP-102 for Gastroparesis in Patients With Diabetes Mellitus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00889486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*